Sep 11, 2024
The human organoids market size is projected to reach USD 1,901 million by 2025, at a CAGR of 17.5%. Report provides crucial industry insigh
seen from United States
seen from China
seen from United States
seen from United States
seen from Germany
seen from United States
seen from United States
seen from United States
seen from T1
seen from Japan
seen from Malaysia
seen from Malaysia
seen from Türkiye
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from Germany
The human organoids market size is projected to reach USD 1,901 million by 2025, at a CAGR of 17.5%. Report provides crucial industry insigh
Human Liver Models Market
Liver is a vital organ that performs several important bodily functions including bile production for digestion, protein production, synthesis of blood clotting factors, storage of glucose (sugar) in the form glycogen, and detoxification.
Download Free Research Report Sample PDF: https://cutt.ly/kXce16w
Human Liver Models Industry - Major Factors Boosting the Future | Emerging Trends
Objectives of this Study:- # To define, measure, and describe the global human liver model market by type and region
# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW Global Market Dynamics Major Industry Growth Drivers: # Growing Focus on Developing Alternatives for Animal Testing Models # Significant Increase in Research Funding and Venture Capital Investments for the Development of Liver Organoids # Growing Initiatives to Increase Awareness about Liver Organoids # Increasing Research Activities on Liver Organoids # Increasing Prevalence of Non-Alcoholic Fatty Liver Disease # Growing Need for the Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late-Stage Drug Failure Looking Out for More Details | Download the PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468 Major Growth Restraints: # Issues Related to the Incorporation of Organoids into Existing Workflows Opportunities: # Increasing Focus on Drug Discovery Activities # Rising Demand for Liver Transplantation # Growing Healthcare Market in the Asia Pacific and Latin America Industry’s Revenue Growth Expectations: The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022). Geographical Growth Scenario: Geographic segments in this report include North America, Europe, Asia Pacific, and the RoW. Of these, the North American segment accounted for the largest share of the market in 2017. The human liver market for North America is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, increasing government funding, growing incidence of NAFLD, and unavailability of livers for transplantation, increasing investments on research, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals. Read More: https://www.marketsandmarkets.com/PressReleases/human-liver-model.asp Leading Market Players: The major players in the global human liver model market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan). The global liver 3D bioprinting market was dominated by Organovo Holdings, Inc. (US). With its broad product portfolio, Organovo Holdings, Inc. held the leadership position in the global 3D bioprinting market for liver in 2016. Its large market share is attributed to its robust 3D bioprinting portfolio. In addition, the company is focusing on various strategies to expand its product offerings and increase its visibility in the 3D bioprinting market. In line with this, the company has collaborated with various research organizations and pharmaceutical companies for developing novel products. For instance, in June 2016, Organovo collaborated with the University of California, San Francisco (UCSF) for developing 3D bioprinted tissues, to be used for research on skeletal disease. Similarly, in December 2014, Organovo collaborated with the Yale School of Medicine, Department of Surgery (US) with the aim to develop 3D organ tissues for surgical transplantation research. Target Audience:
# Pharmaceutical and biotechnology companies # Chemical companies # Cosmetic product manufacturers, suppliers, and distributors # Healthcare providers and diagnostic laboratories # Manufacturers of 3D Cell Culture products # Food & beverage manufacturers # Contract research organizations (CROs) # Research institutes/universities # Research and consulting firms # Venture capitalists
[37 Pages Report] The global human liver models market was valued at USD 1.23 Billion in 2016 and is projected to reach USD 2.56 Billion by 2022, at a CAGR of 13.6% during the forecast period. Base year considered for the report is 2016 and the forecast period considered for this report is 2017–2022.
Human Liver Models Market - Global Market Leaders
Browse 7 market data Tables and 2 Figures spread through 37 Pages and in-depth TOC on "Human Liver Models Market"https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market-171046468.html Early buyers will receive 10% customization on reports. [37 Pages Report] The global human liver models market was valued at USD 1.23 Billion in 2016 and is projected to reach USD 2.56 Billion by 2022, at a CAGR of 13.6% during the forecast period. Base year considered for the report is 2016 and the forecast period considered for this report is 2017–2022. Objectives of the Study:
To define, measure, and describe the global human liver model market by type and region
To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW
Download the PDF Brochure for More Details@ http://bit.ly/2SAS340 CN Bio held the leading position in the global liver-on-a-chip market in 2016. The company offers its products and services for drug discovery and drug safety programs. To enhance its production capabilities and applications, the company focuses on adopting inorganic strategies such as collaborations and agreements. Over the last three years, CN Bio has been a part of six such initiatives that helped the company enhance its presence in this market. For instance, in 2017, CN Bio collaborated with AstraZeneca (UK) to validate a new in vitro tool to predict optimized drug dosing regimens for multi-drug therapies. Furthermore, in 2015, CN Bio collaborated with Alnylam Pharmaceuticals (US) to test and develop therapeutics for liver diseases and infections by using LiverChip, CN Bio’s human liver-on-a-chip platform. The global liver 3D bioprinting market was dominated by Organovo Holdings, Inc. (US). With its broad product portfolio, Organovo Holdings, Inc. held the leadership position in the global 3D bioprinting market for liver in 2016. Its large market share is attributed to its robust 3D bioprinting portfolio. In addition, the company is focusing on various strategies to expand its product offerings and increase its visibility in the 3D bioprinting market. In line with this, the company has collaborated with various research organizations and pharmaceutical companies for developing novel products. For instance, in June 2016, Organovo collaborated with the University of California, San Francisco (UCSF) for developing 3D bioprinted tissues, to be used for research on skeletal disease. Similarly, in December 2014, Organovo collaborated with the Yale School of Medicine, Department of Surgery (US) with the aim to develop 3D organ tissues for surgical transplantation research. You Can Also Get In-Touch with Our Research Experts for More Detailed Information Target Audience:
Pharmaceutical and biotechnology companies
Chemical companies
Cosmetic product manufacturers, suppliers, and distributors
Healthcare providers and diagnostic laboratories
Manufacturers of 3D cell culture products
Food & beverage manufacturers
Contract research organizations (CROs)
Research institutes/universities
Research and consulting firms
Venture capitalists
Scope of the Report:
The research report categorizes the human liver model market into the following segments and subsegments:
Human Liver Model Market, by Type
Liver Organoids
Liver-on-a-chip
2D Models
Animal Models
3D Bioprinting
Human Liver Model Market, by Region
North America
Europe
Asia Pacific
Rest of the World